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1,9-Diazaspiro[5.5]undecanes are dipiperidines spiro-
fused at position 2 of one piperidine ring and at position 4 
of the other (Fig. 1). To the best of our knowledge, this is 
the first review on this compound class and covers the 
literature up until February 2017. The biological activity of 
these compounds, arranged by the type of disorder treated, 
is outlined in the first part of this review. Firstly, com-
pounds based on the 1,9-diazaspiro[5.5]undecane scaffold 
are presented (Fig. 2) and, secondly, compounds with this 
scaffold as derivative of other scaffolds are discussed 
(Section 1.6. Miscellaneous). 
The majority of the compounds studied include an arene 
ring commonly fused at positions 4 and 5 of the diazaspiro 
core. In addition to arene-fused structures, the presence of a 
carbonyl at position 2 is a common feature. Bioactive 
compounds that contain the 1,9-diazaspiro[5.5]undecane 
core always have substituents at position 9 and sometimes 
at position 1. Accordingly, when these diazaspiro com-
pounds are used as substituents on other heterocycles they 
are almost always attached through position 9. 
The second part of this review highlights syntheses of 
the 1,9-diazaspiro[5.5]undecane cores, with each type of 
arene fusion having its own preferable synthesis strategy. 
Substitution options at position 9 and/or 1 are specific for 
each compound and mostly concern the last step of the 
synthesis. Some of these substitution options are exemplified. 
1. BIOLOGICAL ACTIVITY 
This review presents the biological activities of several 
1,9-diazaspiro[5.5]undecanes arranged by the type of 
disorder that was treated and proposed biochemical 
mechanism. For example, in Section 1.1, the treatment of 
obesity may be based on various biological activities of 
1,9-diazaspiro[5.5]undecanes, such as inhibition of acetyl 
CoA carboxylase, antagonism against neuropeptide Y, and 
inhibition of 11β-hydroxysteroid dehydrogenase type 1. 
The pharmacological data are presented (e.g., IC50, EC50, 
AUC, etc.) when reported in the primary sources. 
1.1. Treatment of obesity 
Obesity is a major concern amongst Western civiliza-
tions worldwide. According to the World Health Organiza-
tion (WHO), 1.9 billion adults suffered from overweight in 
2014, of which 600 million were obese.1 Obesity was the 
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global leading cause of death in 2012, and it is associated 
with cancer (e.g., breast, endometrial, ovarian, prostate, 
liver, gallbladder, kidney, and colon cancer), cardiovascu-
lar diseases (e.g., stroke, congestive heart failure, heart 
arrhythmias, and coronary heart disease), osteoarthritis, 
type 2 diabetes mellitus, insulin resistance, hyperlipidemia, 
and increased premature and sudden death.1,2 The data of 
the WHO show3 that the prevalence of obesity in Europe is 
more than 15% in almost every country (see a graphical 
representation in Fig. 3). 
With cardiovascular diseases being the main cause of 
death worldwide, putting a stop to obesity would save 
many lives. Although obesity itself is preventable without 
drugs, developing medicines would partially assist in 
bringing down the number of obese adults. 
Inhibition of acetyl-CoA carboxylase. A biological 
target with regard to the treatment of obesity is the 
inhibition of acetyl coenzyme A carboxylase (ACC). ACC 
is responsible for converting acetyl-CoA into malonyl-
CoA, a step that is vital in fatty acid synthesis. Two 
isoforms of ACC, ACC1 and ACC2, have been identified 
in mammals. Acetyl-CoA is metabolized via the citric acid 
cycle if it is not converted into malonyl-CoA. ACC1 and 
ACC2 are highly expressed in the liver where fatty acid 
Figure 2. Bioactive 1,9-diazaspiro[5.5]undecane derivatives 1–15 used in drug development studies as main scaffolds (Y = CH2, CO;  
X = CH2, CH2CH2, CH=CH). Some hetera analogs will be included for comparison in the discussion (Z = N, O). 
Figure 3. Obesity of adults in Europe in 2015. Obesity incidence: 
green <15%, yellow 15–20%, orange 20–25%, red 25–30%. 
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synthesis and oxidation are important. ACC2, the isoform 
predominantly present in heart and skeletal tissues, 
regulates the amount of fatty acid used in β-oxidation by 
inhibiting carnitine palmitoyl transferase. Inhibition of both 
isoforms would decrease the synthesis of new fatty acids 
and deplete the use of fatty acids stored, thereby resulting 
in weight loss.4 Additionally, ACC inhibitors may be used 
to treat type 2 diabetes mellitus.5 ACC inhibition is expected 
to impact both skeletal muscle and hepatic insulin sensiti-
vity by rebalancing lipid metabolism associated with insulin 
resistance pathogenesis. Menhaji-Klotz and coworkers at 
Pfizer Inc. synthesized many 1,9-diazaspiro[5.5]undecan-
2-ones containing a pyrazole ring fused to positions 3 and 4 
in two different ways to achieve this ACC inhibition.5 IC50 
values for ACC inhibition of 67 and 174 nM were measured 
for compounds 1a and 2, respectively (Fig. 4). Part of the 
same group synthesized a library of 125 3,4-pyrazole-fused 
1,9-diazaspiro[5.5]undecan-2-ones (compounds 1b–o as 
representative examples) and tested them for IC50 values on 
human recombinant ACC1 and ACC2. The smallest IC50 
for ACC1 and ACC2 found were 3.4 and 1.0 nM, 
respectively, both exhibited by compound 1b (Fig. 4).4 
A general trend in dual ACC1/ACC2 inhibition was 
often encountered among the 125 compounds tested: good 
ACC1 inhibition was linked to good ACC2 inhibition.4 The 
same group elaborated on this study by examining the 
structure–activity relationship (SAR) for the pyrazole part 
and the substitution at position 9 of the 1,9-diazaspiro[5.5]-
undecane. In this study, additional pharmacokinetics were 
studied along with the IC50 values for ACC1 and ACC2, 
such as the lipophilic ligand efficiency (LipE), measured 
lipophilicity (ElogD), human liver microsomal incubation 
(HLM), and passive permeability (Papp) in Ralph Russ 
canine kidney cells.6 1,9-Diazaspiro[5.5]undecan-2-one 1c 
(Fig. 4) was selected for a SAR study of the effects of 
modifying the 3,4-pyrazole-fused moiety. Herein it was 
found that decreasing the bulk of the substituent at N-2 
atom of the pyrazole ring (with respect to t-Bu group) 
similarly decreased ACC1/ACC2 inhibition. Increasing the 
bulkiness of this group (tert-pentyl) improved the IC50 
values for both ACC1 and ACC2, but also resulted in an 
increase in HLM by a factor of 4, which outweighed the 
small inhibitory advantage. Introducing substitution at the 
N-1 atom did improve the Papp values, but resulted in too 
much loss of ACC inhibition. Therefore, the tert-butyl-substi-
tuted pyrazole-fused core was used for the further studies. 
The SAR with regard to substitution at position 9 of the 
1,9-diazaspiro[5.5]undecane core was determined for aroyl 
substituents containing a bicyclic fused heteroaryl group. 
Comparisons were made with compound 1c. Compounds 
1d,e showed similar ACC inhibition, HLM clearance, and 
LipE, but only modest improvement of Papp. Compounds 
1f,g showed improved Papp, and good ACC inhibition, but 
LipE values lowered along with higher HLM clearance. 
The very good ACC1 and ACC2 IC50 values of compound 
1g (7 and 3 nM, respectively) were matched by compound 
1h (11 and 5 nM, respectively). Compound 1h was 
designed on results obtained from compounds 1f,g in the 
hope of showing a better LipE value, which it did. The 
downside was the poor Papp value obtained for compound 
1h when compared to compound 1g. Compound 1i showed 
reasonable LipE values and diminished ACC inhibition (74 
and 29 nM for ACC1 and ACC2, respectively), but a 
greatly increased Papp value of 9.7 (×10–6 cm/s) vs 0.8 for 
compound 1h. Based on these results, a further SAR study 
was performed by using isoquinolines and quinolines as 
Figure 4. Compounds used for studying the SAR for ACC inhibition with respect to the substitution at position 9 of the 1,9-diazaspiro-
[5.5]undecane ring system. 
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substituents (compounds 1j–o). The development of amino-
substituted species 1l–o did result in improved thermo-
dynamic solubility at pH 1.2 with a factor up to 10 when 
compared to compounds 1j,k. The Papp values of com-
pounds 1l,m were as bad as those of compound 1h. Efforts 
to improve Papp by increasing the alkylation on the amine 
led to compounds 1n,o exhibiting better Papp than com-
pounds 1l,m. The Papp values of compounds 1n,o were 
still lower than those obtained for compounds 1j,k and, in 
addition, HLM clearance significantly worsened. Com-
pounds 1j,k were chosen for in vivo examination of their 
pharmacological properties. Compound 1j showed the best 
pharmacokinetics with an oral bioavailability of 71%, 
cmax 403 ng/ml, AUC 2070 ng·h/l when administered to rats 
at 5 mg/kg. An intravenous dose of 1 mg/kg in rats demon-
strated a moderate systemic clearance of 29 ml/(min·kg) 
and volume of distribution of 1.7 l/kg. Similarly, com-
pound 1k showed lower bioavailability and better clearance 
and volume of distribution than compound 1j. Different oral 
dosages of compound 1j were administered to rats in combi-
nation with 14C-labeled acetate precursors of lipids. The con-
version of these acetate precursors into their respective lipid 
products for different dosages is shown in Figure 5.6 It became 
clear from these results that compound 1j could be very 
effective in decreasing new fatty acid synthesis and, therefore, 
in treatment of obesity and type 2 diabetes mellitus. 
In a different study performed by Pfizer Inc., ACC inhi-
bitors were explored to treat acne vulgaris.7 Acne vulgaris 
is a skin disease caused by increased sebum secretion and 
manifests when hair follicles become clogged with oil and 
dead skin cells.8 Increased production of sebum is linked to 
both the onset and severity of acne.9 In addition, 80% of 
sebum content is made through de novo fatty acid 
synthesis, which is greatly dependent on ACC.10 Treatment 
of humans with an ACC inhibitor may reduce sebum tri-
glyceride content by 66%.7 In the study carried out by 
Pfizer Inc., compound 1k showed ACC inhibitor activity. 
For this compound, human ACC1/ACC2 (hACC1/hACC2) 
and sebocyte inhibition were measured in a transcreener 
assay and ACC1/ACC2 inhibition was also determined in a 
radiometric assay. IC50 values for the transcreener assay 
were 14 and 3 nM for hACC1 and hACC2, respectively, 
and 94 nM for C9302E sebocytes. Only 2 out of 24 
compounds from the same study showed better IC50 values 
than compound 1k for hACC1/hACC2 inhibition and only 
one of these also improved on the IC50 value for the 
sebocytes. These two compounds had a 4-azaspiro[5.5]-
undecane core structure (similar to that of 1,9-diazaspiro[5.5]-
undecane with the nitrogen at position 1 replaced by 
carbon). For the radiometric assay of compound 1k, the 
IC50 values obtained were 11 and 4 nM for hACC-1/hACC-2, 
respectively; values that were in the highest order along 
with six other compounds.7 Further in vivo testing was not 
performed with compound 1k, but its effectiveness as 
ACC1/ACC2 dual inhibitor is apparent. 
Neuropeptide Y antagonism. Another study, developed 
by Poindexter et al., showed that 4,5-benzene-fused 
1,9-diazaspiro[5.5]undecanes 3a–n (Fig. 6) presented anta-
gonistic activity against neuropeptide Y (NPY).11 
NPY is a 36-amino acid neuropeptide that was found to 
be one of the most important regulators of feeding behavior 
and energy homeostasis. NPY is most abundant in the brain 
and has a high expression in the hypothalamus.12 Further-
more, NPY is expressed in the spinal cord and most sympa-
thetic nerve fibers, especially around blood vessels. Anta-
gonism of the NPY receptors (NPY Y1–Y5) has been 
related to reduced food-intake in mammals,11 making NDY 
antagonists drug candidates for the treatment of obesity. 
Various studies with mice have shown that especially the 
NPY Y1 and NPY Y5 are important targets for treating 
obesity.13 The treatment of obesity by NPY Y5 antagonism 
works in two ways. Firstly, it was found that food 
consumption was lowered by 10% in diet-induced obese 
mice. Secondly, the chronic treatment with NPY Y5 
antagonists inhibited the reduction of the metabolic rate. 
This indicated that NPY Y5 antagonists could be used to 
prevent decrease in energy expenditure due to dieting or 
other anti-obesity treatments.2 It was also shown that the 
combination of food restriction and administration of an 
NPY Y5 antagonist was more successful in giving weight 
loss than either treatment alone.2 
In developing an approach to treat obesity, it was herein 
suggested that combination of an NPY Y5 antagonist and 
Figure 5. Conversion percentage of 14C-labeled acetate precursors 
into their lipid products vs mg/kg of compound 1j administered in 
rats.6 Reprinted (adapted) with permission. Copyright 2013 
American Chemical Society. 
Figure 6. Compounds 3a–n tested for NPY antagonism. 
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an anti-obesity drug would be effective in treating humans.2 
Furthermore NPY Y5 antagonism was demonstrated by 
compounds containing the 1,9-diazaspiro[5.5]undecane 
structural moiety.2 Characterization of the bioactivity was 
performed by employing insect cells (BRI-TN-5BI-4) 
infected with NPY Y5-recombinant Baculovirus. The 
radioligand used was iodine-125 labeled PYY ligand. 
Herein the IC50 values of compounds 3a–n were less than 
10 μM, with compounds having an IC50 of less than 
500 nM or less than 100 nM.11 The results of this binding 
assay showed that these compounds may be used in 
treatment of disorders that are characterized by an excess 
of NPY, including cardiovascular diseases, renal system 
disorders, cerebral diseases, conditions of pain or 
nociception, abnormal food intake disorders, inflammation 
disorders, sleep disturbance, and diabetes. When it comes 
to the treatment of obesity, compounds 3a–n are expected 
to have an effective dose in the range of 0.05–1 mg/kg 
bodyweight if administered parenterally, and of 1–20 mg/kg 
bodyweight if administered orally. 
Inhibition of 11β-hydroxysteroid dehydrogenase type 1. 
Inhibition of 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1) by compounds with the diazaspiro moiety 
may also combat obesity amongst other diseases. This was 
the conclusion drawn after a study performed by Claremon 
and coworkers on compounds 4a–d (Fig. 7) that presented 
significant 11β-HSD1 inhibitory activity (IC50 < 100 nM).14 
major potential for treatment of obesity.19–22 Since it was 
found that the MCH-R1 was highly conserved between 
rodents and humans, the results obtained in rodents con-
cerning MCH and MCH-R1 antagonism could serve as a 
model for assessment of MCH-R1 antagonism in humans. 
MCH mRNA was overexpressed in the hypothalamus of 
diet-induced obese rats and mice, as well as in leptin-
deficient ob/ob mice, fasting leptin-deficient ob/ob mice 
and their control mice, and in leptin-resistant fa/fa Zucker 
rats.21 In addition, MCH-R1-knockout mice are lean, hypo-
phagic, hyperactive, have increased metabolic rate and 
reduced fat mass, and are resistant to diet-induced obesity.23 
MCH also increases the release of NPY, a contributor to 
feeding behavior as mentioned earlier.21 This means that 
inhibition of MCH production or of its MCH-R1 receptor 
could have direct and indirect effects resulting in treatment 
of obesity. 
4,5-Benzene-fused 1,9-diazaspiro[5.5]undecane deriva-
tives 5a–c (Fig. 8) presented the good binding affinities of 
13, 16, and 11 nM, respectively, for MCH-R1. In this 
study, the SAR of related compounds was also examined. It 
was found that substitutions at position 9 of the 1,9-di-
azaspiro[5.5]undecane core other than alkyl groups (e.g., 
sulfonyl, acyl, carbamoyl groups) significantly reduced the 
MCH-R1 binding affinity of such compounds.23 Following 
this trend, it was concluded that having the basic nitrogen 
on position 9 of the diazaspiro moiety was an important 
condition for binding MCH-R1. A pharmacokinetics study 
of compound 5b showed an AUC of 332 ng·h/ml in rats.23 
Figure 7. 11β-HSD1 inhibitors 4a–d. 
11β-Hydroxysteroid dehydrogenase pre-receptor control 
enzymes that modulate activation of the glucocorticoid 
receptor and the mineralocorticoid receptor via regulation 
of glucocorticoid hormones.15–17 Glucocorticoids (e.g., 
cortisol) are steroid hormones that regulate fat metabolism, 
function, and distribution, as well as carbohydrate and 
protein metabolism. Therefore, inhibition of 11β-HSD1 
may prove useful in treating multiple glucocorticoid-related 
disorders and/or aspects of the metabolic syndrome. 
Examples include combatting obesity, glucose intolerance, 
insulin resistance, hyperglycemia, hypertension, and hyper-
lipidemia.14 
Melanin-concentrating hormone antagonism. Another 
way in which compounds containing 1,9-diazaspiro[5.5]-
undecane moiety may treat obesity is by exhibiting antago-
nizing activity toward melanin-concentrating hormone 
receptor 1 (MCH-R1).18 MCH-R1 is a member of the G 
protein-coupled receptors and binds MCH, a hypothalamic 
cyclopeptide. Targeting MCH-R1 is mentioned as having a 
1.2. Treatment of central nervous system disorders 
Orexin antagonism. The family of diazaspiro[5.5]-
undecanes, including the 1,9-diazaspiroundecanes, was also 
used to develop orexin antagonists. Orexins A and B, also 
known as hypocretins, are small neuropeptides that are 
produced in discrete neurons of the lateral hypothalamus 
and that bind to G-protein-coupled receptors. Orexins are 
recognized as important targets for treating sleep dis-
orders24 (e.g., narcolepsy and insomnia) and are also 
considered vital in regulating feeding, metabolism, and 
energy homeostasis.25 Orexins may also be involved in 
psychiatric/neurological disorders like Parkinson disease, 
Huntington disease, Tourette syndrome, and epilepsy, as 
well as involvement in cardiovascular diseases, heart and 
lung diseases, and multiple sorts of pain.26 
Figure 8. MCH antagonists 5a–c. 
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In the treatment of sleep disorders, antagonists for both 
orexin receptors (OX1R and OX2R) were developed based 
on the 1,9- and 2,9-diazaspiro[5.5]undecane cores.27 The 
aim of this research performed by Hoyer and coworkers 
was to develop a dual antagonist against OX1R and OX2R, 
as well as a selective OX2R antagonist to distinguish the 
effects of both receptors on sleep behavior. The SAR was 
studied for a number of structures 6a–f with respect to both 
substitution at positions 1 and 9 (Fig. 9). 
comorbidities like depression, anxiety, and insomnia. 
Existing pain therapies, which use nonsteroidal anti-inflam-
matory drugs, opioid agents, calcium channel blockers, and 
antidepressants, exhibit limited efficacy and a range of side 
effects, limiting their usefulness in chronic pain treatment. 
In addition, pain is often multimodal, making the use of 
monomodal treatment not able to relieve all of the pain. 
The multimodal activity of the compounds containing the 
1,9-diazaspiro[5.5]undecane core against multiple receptors 
associated with pain or side effects related to pain could 
make this class of compounds of high interest in new 
treatments of pain. 
The most effective compounds in suppressing pain are 
the opioids (e.g., morphine), mainly through their acti-
vation of the μ opioid receptor. The side effects associated 
with the use of opioids are also the most severe and can 
include derangement, hallucination, nausea, constipation, 
respiratory depression, and addiction.29,30 In addition, 
opioids have not proven useful in the treatment of chronic 
pain, as demonstrated by morphine. Morphine has only a 
limited effectiveness against chronic pain of neuropathic or 
inflammatory origin, opposed to greatly diminishing acute 
pain. Furthermore a tolerance for morphine is built up in 
the body, which leads to an increase of dosage to maintain 
the same pain-suppressing effects. Weaker opioid analge-
sics, like pentazocine, are less effective at suppressing 
strong pain and display the same side effects, albeit less 
intense.31 Some of the mentioned side effects are associated 
with an activation of the dopamine D2 receptors.32 
Antagonistic activity against the dopamine D2 receptor has 
also been linked to reducing the addictive effect of opioid 
analgetics.32 Therefore, the possible combination of μ opioid 
and dopamine D2 antagonistic activity may lead to deve-
lopment of new pain-control agents with reduced or sup-
pressed side effects.32 Studies with mice have also shown 
that σ1 receptor antagonism may also relieve neuropathic 
pain and address some comorbidities (e.g., anhedonia, a 
core symptom in depression) related to pain states.30 
The Ki values, for both the σ1 and μ receptors, were 
determined for compounds 7a–d in a study developed by 
Virgili-Bernado et al.33 (Fig. 10). Compounds 7b–d 
showed good dual σ1/μ inhibition with Ki for both receptors 
between 100 and 500 nM. Of the compounds with a core of 
closely related 4-oxa-1,9-diazaspiro[5.5]undecanes, 48 
derivatives were tested of which only compounds 7e–g 
performed better than compounds 7b–d with Ki values for 
both receptors lower than 100 nM. 
Figure 9. 1,9-Diazaspiro[5.5]undecan-2-ones 6a–f tested for dual 
OX1R/OX2R antagonism and selective OX2R antagonism. 
Compound 6a was taken as a starting point. Introduction 
of small substituents (e.g., methyl groups) on the benzyl 
group led to compound 6b, which exhibited a more than 
tenfold increase in inhibition of both OX1R and OX2R. The 
lipophilicity of compound 6b was, however, too high and 
substitution with monoaryl groups (e.g., pyridines) resulted 
in loss of inhibition potency. The introduction of bicyclic-
fused aryl substituents led to compounds 6c,d, which 
showed a similar increase in inhibition for both OX1R and 
OX2R, whilst also favorably reducing the lipophilicity. The 
SAR study was then carried out for substitution at position 9. 
When testing compounds 6d–f, it was observed that OX2R 
inhibition was maintained in a high range, whereas OX1R 
values greatly varied, leading to more selective OX2R  
antagonists like compound 6e. For compound 6d, an 
excellent subnanomolar Ki was obtained for OX2R (pKi  
9.34). When examined in vivo such compounds, containing 
the 1,9-diazaspiro[5.5]undecane core, were found 
ineffective. A high blood clearance and volume distribution 
were found (188 ml/(min·kg) and 3.1 l/kg, respectively), 
along with poor cmax (18 nM), AUC (31 nM·h) and oral 
bioavailability (5%). The 2,9-diazaspiro[5.5]undecane 
performed much better in in vivo testing and it was 
suggested that poor in vivo performance is directly related 
to the 1,9-diazaspiro[5.5]undecane core.27 
σ, μ, and D2 receptors. The treatment of pain in general 
has always been important because one out of five adults 
suffer from pain and one out of ten are diagnosed with 
chronic pain each year.28 The incidence of pain is only 
increasing due to population ageing and is often related to Figure 10. Dual σ1/μ inhibitors 7a–g. 
Chemistry of Heterocyclic Compounds 2017, 53(8), 827–845 
833 
Calcitonin gene-related peptide antagonism. The calci-
tonin gene-related peptide (CGRP) is a neuropeptide that 
has two forms in humans: α-CGRP and β-CGRP. α-CGRP 
plays a central role in migraine pathology, migraine being a 
disease that affects 12% of the population.34 CGRP and its 
receptor are widely expressed in both the central and 
peripheral nervous system by multiple cell types which are 
involved in the regulation of inflammatory and nociceptive 
response.34,35 Although the compounds developed with the 
aim of inhibiting CGRP do not exclusively contain the 
1,9-diazaspiro[5.5]undecane core, even some measure of 
CGRP inhibition could be useful. This usefulness might be 
expressed in a multimodal activity against the CGRP 
among others, possibly giving rise to the improved effec-
tiveness of the diazaspiro compounds when treating, for 
example, obesity or (chronic) pain. The usefulness of 
combining compounds that may inhibit CGRP with one or 
more other compounds to provide more effective remedy 
against multiple diseases is also recognized. Proposed is 
the use of such CGRP inhibitors in conjunction with anti-
migraine agents, potentiators such as caffeine, anti-emetics, 
ergot alkaloids, beta-adrenergic antagonists, interleukin 
inhibitors, and gap junction inhibitors.35 
An attempt developed by Chaturvedula and coworkers at 
finding structures that would effectively inhibit the CGRP 
receptor focused on many spiro compounds, including the 
4,5-benzene-fused 1,9-diazaspiro[5.5]undecan-2-one 8a 
(Fig. 11).36 IC50 and EC50 values of 29 and 15 nM, 
respectively, were obtained for this compound. The closely 
related structure 8b, a 4,5-benzene-fused 1,3,9-triazaspiro 
derivative, gave an even better result in the same study 
with IC50 and EC50 values of 5 and 3 nM, respectively.36,36 
system, neurogenic inflammation, and smooth muscle cont-
raction. Since an NK1 antagonist may inhibit the binding 
of substance P to NK1, administration of an NK1 anta-
gonist may prove useful in treatment of these diseases.38 
SR140333, a known inhibitor of NK1 (Fig. 12), was 
examined and had an IC50 of 0.31 nM for binding NK1.38 
Figure 11. CGRP inhibitors 8a,b. 
1.3. Immune system and cell signaling disorders 
Neurokinin receptor antagonism. The neurokinin 
receptors (NK1, NK2, and NK3) that form the well-known 
NK receptor class are widely present in the central and 
peripheral nervous system. These receptors are modulated 
by tachykinins, a family of neurotransmitter peptides, and 
play an important role in functioning as a biowarning 
system. Destruction of such a system may result in several 
diseases like pain, anxiety, irritable bowel syndrome (IBS), 
and obstructive bronchial diseases.37 The NK1 receptor 
mediates biological responses exhibited by substance P, 
which include pain transmission, activation of the immune 
Compound SR140333 presents a 4-phenylquinucli-
dinium core. Upon replacing this moiety with the 
4,5-benzene-fused 1,9-diazaspiro[5.5]undecane core, com-
pound 9a (Fig. 13) was obtained with similar substitution at 
position 9 and with an IC50 value of 31 nM for NK1 
binding.38 
Oi-Pr
O
Cl
Cl
N
Cl
N
SR140333
Figure 12. NK1 antagonist with an excellent IC50 value. 
NHY
Oi-Pr
O
Cl
Cl
N
X
a X = N, Y = CH2
b X = N, Y = CO
c X = N+Me I–, Y = CH2
d X = N+Me I–, Y = CO9a–d
Figure 13. Compounds 9a–d based on SR140333 tested for NK1 
antagonist activity. 
Additionally, having a carbonyl at position 2 of the 
benzene-fused diazaspiro core increased the IC50 value to 
54 nM for compound 9b. Methylation of compounds 9a,b 
yielded salts 9c,d with IC50 values of 2.0 and 1.9 nM, 
respectively. Animal testing on substance P-induced 
bronchoconstriction in guinea pigs showed ID50 values of 
24 and 19 μg/kg for compound 9d and SR140333, 
respectively.38 This example showed that the 1,9-diazaspiro-
[5.5]undecanes with a fused benzene ring could be used as 
effective NK1 antagonists. 
The NK2 receptor can be selectively stimulated to 
control smooth muscle contraction associated with asthma, 
pulmonary irritations, intestinal spasms, and kidney 
infections.39 The administration of NK antagonists can be 
effective in treatment of such diseases.37,39,40 
Development of dual NK1/NK2 antagonists was also 
explored.41–45 Although the cited works were not mainly 
concerned with the 1,9-diazaspiro[5.5]undecane core, two 
of such structures (Fig. 14) were examined in their role as 
tachykinin antagonist (for NK1 and NK2) in bladder 
contraction in test animals.45 Herein it was found that 
fumarate YM-44778 exhibited high binding affinities of 
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pKi 8.08 and 8.55 for binding NK1 and NK2, respectively, 
transfected in Chinese hamster ovary cells (CHO-K1). A 
related fumarate YM-44781 also exhibited high binding 
affinity in similar conditions, giving pKi 9.09 and 9.94 for 
NK1 and NK2, respectively. In drug-induced bladder 
contraction, antagonism of these contractions was observed 
after administration of YM-44778 and YM-44781 
(IC50 100 and 27 μg/kg bodyweight, respectively). It was 
concluded that YM-44781 was a potent NK2 antagonist 
and that YM-44778 was a nonselective NK1/NK2 anta-
gonist. 
A large study aimed at finding NK1/NK2 dual anta-
gonists for treating an inflammatory disease produced a 
compound library of more than 11,000 compounds.46 Some 
of these compounds contained either the 4,5-benzene-fused 
1,9-diazaspiro[5.5]undecan-2-one (compounds 10a,b) or a 
1-acetylated 4,5-benzene-fused 1,9-diazaspiro[5.5]undecane 
(compounds 10c–d) moiety substituted at position 9 (Fig. 15). 
The conclusion of the study was that the investigated 
compounds exhibited strong activity against both NK1 and 
NK2 receptors. 
In a study carried out by Brugger and coworkers, two 
3,4-benzene-fused 1,9-diazaspiro[5.5]undecan-2-ones 11a,b 
(Fig. 16) were tested for their ability to allosterically 
modulate mGluR4.50 The biological assay was performed 
by means of a cAMP assay using HEK-293 mGluR4 cells 
with EC20 L-glutamate (2.3 and 4.3 μM for mGluR4 and 
mGluR6, respectively). EC50 values were determined and 
were found to be between 1 and 10 μM for both 
compounds 11a,b. Several 1,5,9-triazaspiro[5.5]undecanes 
showed better EC50 values at below 1 μM concentrations. 
Figure 14. 1,9-Diazaspiro[5.5]undecanes possessing dual  
NK1/NK2 antagonism. 
Figure 15. Compounds 10a–d designed for dual NK1/NK2 
antagonism. 
Allosteric modulators of metabotropic glutamate 
receptor subtype 4. Compounds that modulate metabo-
tropic glutamate receptor subtype 4 (mGluR4) by allosteric 
mechanism may also alter glutamate level or glutamatergic 
signaling or do so instead of allosteric modulation. Glu-
tamate is an amino acid transmitter in the central nervous 
system. Glutamate is involved in many physiological 
functions (e.g., learning, memory, sensory perception, 
motor control, respiration, cardiovascular function), as well 
as in neurological and psychiatric diseases, caused by an 
imbalance in glutamatergic neurotransmission.47–49 
Inhibition of chemokine receptors CXCR3. Chemo-
kines are chemotactic cytokines that are involved in 
immune system cell signaling.51 Chemokines are bound by 
chemokine receptors (e.g., CCR1–CCR9, CXCR1–
CXCR5), which are G protein-coupled transmembrane 
receptors. In particular, the CXCR3 chemokine receptor is 
activated by three chemokines: IP-10, Mig, and I-TAC.52 
CXCR3 is expressed in the T cells, B cells, and NK cells 
among others. T cells are known to participate in auto-
immune diseases (e.g., multiple sclerosis, rheumatoid 
arthritis, atherosclerosis, type I diabetes), allergic diseases 
(e.g., bronchial asthma, transplanted organ rejection) and 
they generate interfusions in immunologic diseases (e.g., 
psoriasis). Since CXCR3 is involved in migration and 
accumulation of T cells, inhibition of CXCR3 by an 
antagonist could be useful in the treatment of the 
aforementioned diseases. In addition, CXCR3 is expressed 
in the neoplasm of a malignant B cell system, making a 
CXCR3 antagonist effective for carcinomatous immuno-
therapy, metastasis control in particular. All this would 
make CXCR3 antagonists useful therapeutic agents in 
treatment, prevention or suppression of carcinoma diseases 
(e.g., leukemia, cancer metastasis), metabolism-related 
diseases (e.g., diabetes), infections or diseases with an 
infection (e.g., AIDS, SARS), allergic diseases, auto-
immune diseases, gastrointestinal diseases (e.g., Crohn's 
disease, colitis ulcerosa), respiratory diseases, and neuro-
logic diseases (e.g., infarct, thrombosis). Compounds 12a,b 
were tested for CXCR3 inhibition53 (Fig. 17). Compound 
12b presented better results with an IC50 value of 1.1 μM. 
Figure 16. Modulators of mGluR4 11a,b. 
Figure 17. Compounds 12a,b tested for CXCR3 inhibition. 
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1.4. Cardiovascular disorders 
Inhibition of aldosterone synthase. Aldosterone synthase 
is expressed in the adrenal cortex and synthesizes the 
steroidal hormone aldosterone. Aldosterone production and 
secretion are regulated by the adrenocorticotropic hormone 
(ACTH), angiotensin II, and sodium and potassium ions.54 
Aldosterone reabsorbs sodium ions from the renal filtrate 
and secretes potassium ions into the renal filtrate. 
Treatment or delaying of states such as congestive heart 
failure, coronary heart disease, acute and chronic renal 
failure, metabolic syndrome and fibrosis among others 
could be done by employing cytochrome P450 aldosterone 
synthase (CYP11B2) inhibitors. Another function of ACTH is 
to regulate the production of cortisol, making inhibition of 
ACTH also interesting for the treatment of the cortisol-
related disorders mentioned earlier, such as obesity.55 
Within the large variety of arene-fused diazaspiro 
compounds available, a rare 1,2-imidazole-fused derivative 13 
containing the 1,9-diazaspiro[5.5]undecane core, was 
synthesized and tested as inhibitor of aldosterone synthase 
(Fig. 18).55 Compound 13 specifically inhibited CYP11B2 and 
could therefore be used to treat states related to aldosterone.  
1.5. Psychotic disorders 
Inhibition of phosphodiesterases. Phosphodiesterases 
(PDE) are a class of intracellular enzymes involved in 
hydrolysis of cyclic adenosine monophosphate (cAMP) 
and cyclic guanosine monophosphate (cGMP) into the 
corresponding nucleotide monophosphates.58 cAMP and 
cGMP mainly serve as secondary messengers in regulating 
intracellular processes in neurons of the central nervous 
system.59 The function of PDEs in the neurons is to activate 
cAMP- and cGMP-dependent kinases and subsequently 
phosphorylate proteins involved in acute regulation of 
synaptic transmission, neuronal differentiation and 
survival. A main mechanism for regulating cyclic 
nucleotide signaling is phosphodiesterase-catalyzed cyclic 
nucleotide catabolism. There are 11 families of PDEs, 
encoded by 21 genes.59 Each gene can also yield splice 
variants, which increases the isozyme diversity. PDE 
families are functionally distinguished based on cyclic 
nucleotide substrate specificity, mechanisms of regulation, 
and sensitivity to inhibitors. PDEs are differentially 
expressed throughout the organism. Depending on the 
function and localization of the different PDE isozymes, 
they may serve distinctly in different physiological 
functions. These functions may mean that selective inhibition 
of a particular PDE family could result in selective 
treatment of disorders, possibly with fewer side effects. 
Thus inhibitors of such an enzyme, PDE10, could be 
used in the treatment of psychotic disorders, such as 
Huntington's disease, schizophrenia, obsessive-compulsive 
disorder, drug-induced psychosis, and delusional disorders. 
According to the study developed by Humphrey, inhibition 
of the PDE10 family of isozymes could be achieved by 
some derivatives of 9-(phthalazin-1-yl)-1,9-diazaspiro[5.5]-
undecanes 15a–d (Fig. 20).59 
Figure 18. Compound 13 tested for 
inhibition of aldosterone synthase. 
Low-density lipoprotein binding in human blood 
plasma. Low-density lipoproteins (LDL) are involved in 
causing atherosclerosis unless their oxidation is inhibited. 
A natural control agent is considered to be α-tocopherol, a 
major form of vitamin E, which acts as chain-breaking 
antioxidant by inhibiting LDL oxidation in plasma.56 In an 
attempt to make a synthetic analog of α-tocopherol, 
multiple steroidal structures were made, as well as two 
2,3-benzene-fused 1,9-diazaspiro[5.5]undecanes 14a,b 
(Fig. 19).57 Additionally, α-tocopherol mimics are inte-
resting, since they may improve natural protection against 
radical species (e.g., superoxide). In order to be a success-
ful mimic, a molecule should be able to form a stable 
radical cation at an ionization potential of 0.45–0.65 V. 
The 1,9-diazaspiro[5.5]undecanes 14a,b were effective at 
forming such a stable radical cation with redox couples at 
0.6 V. A lower amount of these diazaspiro compounds was 
bound (ca. 25%) to the LDL, which meant that these 
derivatives were not further examined in this study. 
Figure 19. Compounds 14a,b 
studied as α-tocopherol analogs. 
1.6. Miscellaneous 
Inhibition of epidermal growth factor receptor 
T790M kinase and oxytocin antagonists. Further use of 
the 1,9-diazaspiro[5.5]undecane core can be found as a 
substituent for other heterocyclic drugs used for treating a 
variety of disorders. One such disorder is the non-small cell 
lung cancer (NSCLC).60 A mutation of the epidermal 
growth factor receptor (EGFR) at position 790 occurs in 
about half the patients suffering from this disorder. This 
T790M mutation replaces a threonine with a methionine. 
Irreversible inhibition of EGFR T790M kinase was shown 
to inhibit cell proliferation of cell lines expressing the 
EGFR T790M mutation and regress tumor volume in mice 
Figure 20. Compounds 15a–d 
studied as inhibitors of PDE10. 
N
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15 a R = H, b R = Cl,
c R = CN, d R = CO2H
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with EGFR T790M/L858R resistant mutation. To this end, 
a library of 254 tetrasubstituted pyrazines was developed, 
one of which contained the diazaspiro moiety (compound 
16, Fig. 21), but the activity was only reported for selected 
examples.61 
fatty liver development, insulin resistance, increased fat 
mass, and abnormal glucose tolerance when fed a high-fat 
diet. In addition, energy expenditure was accelerated and 
transplantation of adipose tissue from DGAT1 knockout 
mice to wild-type mice resistant to obesity induced by a 
high-fat diet. On the other hand, DGAT1 overexpression in 
mice resulted in worsening of diabetes mellitus and 
obesity. These results led to the conclusion that DGAT1 
inhibitors could be therapeutic drugs for treatment of 
obesity, type 2 diabetes mellitus, coronary artery disease, 
arteriosclerosis, lipidosis, fatty liver, metabolic syndrome, 
hypertension, and cerebrovascular disease.65 
In a study developed by Liu et al. to treat obesity via the 
pathway described above, a 1,9-diazaspiro[5.5]undecan-
2-one moiety was used as substituent on benzimidazole 
derivatives exemplified by compound 18 (Fig. 23).65 In this 
study, compound 18 presented an IC50 value of 49.0 nM. 
The lowest and highest values among the 173 compounds 
of the study were 1.56 and 2000 nM, respectively. 
Figure 21. Pyrazine 16 – a possible EGFR T790M kinase inhibitor. 
In a different study, a library of 3,5-disubstituted 
4-(pyridin-3-yl)-1,2,4-triazoles was developed with the aim 
of finding oxytocin antagonists. This library included three 
compounds 17a–c (Fig. 22) with the 1,9-diazaspiro[5.5]-
undecan-9-yl group as substituent.62 
Figure 22. Oxytocin antagonists 17a–c with a 1,2,4-triazole core. 
Therapeutic use of oxytocin antagonists concentrates 
also on sexual dysfunctions, particularly premature 
ejaculation. All the compounds of this study exhibited 
oxytocin antagonist activity, expressed as a Ki value, of less 
than 1 μM.62 
Quinoxaline derivatives sometimes containing substi-
tution at the 1,9-diazaspiro[5.5]undecane core, could be 
used as dopamine receptor antagonist, corticosteroid, 
β2-adregenic agonist, leukotriene modifier, antihistamine, 
decongestant, antitussive, and nonsteroidal anti-inflam-
matory drug. The substituted quinoxalines were developed 
as CRTH2 inhibitors and can be used for treatment of 
symptoms and diseases associated with uncontrolled 
CRTH2 stimulation, such as the aforementioned.63 
Inhibition of diglyceride acyltransferase. It has been 
noted that the main cause of obesity is the accumulation of 
triacylglycerol (TG) in adipose tissue, caused by excessive 
caloric intake. There are two pathways that synthesize TG: 
a glycerol pathway in organs and a monoacylglycerol 
pathway involved in aliphatic acid absorption from the 
small intestine. The final step in TG synthesis of both these 
pathways is catalyzed by diglyceride acyltransferases 
(DGATs).64 Of the two subtypes, DGAT1 is present in the 
adipose tissue, the liver, and the small intestine and is 
involved in lipid absorption in the small intestine, lipid 
accumulation in the fat cells and in the liver. DGAT1 
knockout mice have been demonstrated to be resistant to 
Figure 23. Compound 18 –  
a possible inhibitor of DGAT1. 
Histamine receptor ligands. In developing an agent 
that focuses on the treatment of neuropathic pain, the 
histamine H4 receptor (H4-R) has been one of the targets.66 
This receptor is also a member of the G protein-coupled 
receptor family, and it binds histamine to transduce signals 
to modulate cellular activities. Antagonists of H4-R or 
inverse agonists may treat multiple types of pain (e.g., 
inflammatory pain, chemically induced pain, post-surgery 
pain, pain from osteoarthritis, and neuropathic pain). In this 
study, concentration versus response data was analyzed to 
obtain the compound potency as binding constant (Kb) 
values for antagonists and inverse agonists and as EC50 
values for partial agonists. All the compounds tested 
blocked the ability of histamine to increase Ca2+ 
concentrations in cells and had Kb values between 4 and 
1000 nM (not reported for all compounds). One single 
example of a 1,9-diazaspiro[5.5]undecane derivative 
(compound 19, Fig. 24) was present among them, which 
contained a [d]-fused pyrimidine ring.67 
Figure 24. Possible histamine 
H4 receptor antagonist 19. 
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Another research looked into developing the histamine 
H3 receptor (H3-R) inverse agonists. This receptor is 
predominantly expressed in the central nervous system and 
known to control release of several neurotransmitters (e.g., 
norepinephrine, serotonin, GABA, dopamine, and acetyl-
choline).68 Because of this, it has been suggested that H3-R 
antagonists or inverse agonists could be used to treat dis-
orders related to the central nervous system. In animals 
antagonism of H3-R has been shown to enhance wakeful-
ness, improve attentive and cognitive behaviors, and reduce 
feeding and body weight. In this study, a substituted urea 20 
(Fig. 25), containing the 4,5-benzene-fused 1,9-diazaspiro-
[5.5]undecan-2-one moiety, was examined as one of the 
possible antagonists.68 However, compound 20 had an IC50 
value of 783 nM for human H3, which was around a 1000-
fold higher than the best antagonist found in the study. 
pyrazin-1(2H)-one derivatives that could inhibit PARP-1 
were developed. Compound 23 (Fig. 27), containing 1,9-diaza-
spiro[5.5]undecane moiety, had an IC50 for PARP-1 and a 
CC50 for BRCA-1 of 6.2 and 220 nM, respectively. The closely 
related 1,8-diazaspiro[4.5]decane derivative 22 was found 
to have the best pharmacokinetic values in this study (IC50 
of 2.5 nM for PARP-1 and CC50 of 48 nM for BRCA-1).70 
Figure 25. Compound 20 stu-
died for H3-R antagonism. 
Cannabinoid receptor type 2 agonists. The canna-
binoid receptor (CB2 receptor) is a G protein-coupled 
receptor that may modulate inflammation and/or the 
immune system. It is suggested that compounds that bind 
the CB2 receptor may be useful for treating diseases like 
rheumatoid arthritis, immune dysfunction, atopic derma-
titis, carcinomatous pain, etc. In a study aimed at develop-
ment of a CB2 receptor-binding 3,4-dihydroisoquinoline 
derivatives, the 3,4-benzene-fused 1,9-diazaspiro[5.5]-
undecane core was among the structural units considered. 
In compound 21, an alkylidene substituent was found at 
position 2, along with a methylated position 9 (Fig. 26).69 
Figure 26. Compound 21 developed 
for CB2 receptor binding. 
Poly(ADP-ribose) polymerase-1 inhibitors. Another 
use of the 1,9-diazaspiro[5.5]undecane core was found in 
the development of poly(ADP-ribose) polymerase-1 
(PARP-1) inhibitors.70 PARP-1 is an important member of 
the PARP enzyme family which is involved in the DNA 
damage detection and repair. Inhibitors of PARP have been 
demonstrated to prolong the antitumor effects of certain 
anticancer therapies. PARP inhibitors have also been 
demonstrated to work in preclinical models of reperfusion 
injury (stroke, myocardial infection), arthritis, inflam-
mations, and diabetes. Furthermore, PARP inhibitors could 
be used in cancer patients suffering from cancers bearing a 
specific homologous recombination repair defect (BRCA-1 
and BRCA-2 protein deficiency). In this study, pyrrolo[1,2-a]-
Figure 27. Compounds 22 and 
23 as PARP-1 inhibitors. 
Class III antiarrhythmic agent. Arrhythmia can occur 
as complication to cardiac diseases (e.g., myocardial 
infarction and heart failure) and includes irregular, too fast 
or too slow heartbeats and may cause a ventricular 
fibrillation, which could lead to sudden death.71 Of all the 
possible antiarrhythmic agents (classes I–V), the class III 
agents effect potassium levels and selectively prolong the 
duration of the action potential without a depression of the 
maximum velocity of the upstroke of the action potential.72 
As such, class III agents are not considered able to cause a 
myocardial depression or induce arrhythmia like class I 
agents would be. In search for class III antiarrhythmic agents, 
some 3,4-benzene-fused 1,9-diazaspiro[5.5]undecan-5-ones 
were synthesized (compounds 24a–h; Fig. 28).73 The study 
concluded that most of the compounds tested performed 
better than sotalol in the same protocol (EC25 20 μM). 
Figure 28. Class III antiarrhythmic agents 24a–h featuring an 
arene-fused spiro core. 
NH
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Cyclin-dependent kinase inhibitors. Cyclin-dependent 
kinases (CDKs) are involved in cell cycle progression.74 
CDK7 is responsible for activation of other CDKs by 
means of phosphorylation, making it indispensable for any 
type of cell cycle progression.75 In particular, CDK7 is a 
transcription regulator, since it participates in phosphory-
lation of the largest subunit of RNA polymerase II at its 
carboxy terminal domain. As such, inhibition of CDK7 
may be used for treatment of cancer, cardiac hypertrophy, 
and inhibition of virus replication (e.g., HIV, EBV, HCV). 
A study to find anticancer agents developed multiple 
pyrazolo[1,5-a][1,3,5]triazine derivatives, including one 
compound containing the 1,9-diazaspiro[5.5]undecane 
moiety (compound 25) as a substituent (Fig. 29).76 The IC50 
value for CDK7 inhibition of compound 25 was in the 
range of the lowest values of the library (≤5 nM). 
diverse inflammatory cells (e.g., mast cells, B cells, macro-
phages, and neutrophils).79 The immunoreceptors are 
important for mediating allergic diseases and antibody-
mediated autoimmune diseases. For example, Syk has 
already been shown to be important in B cell differentiation 
and activation, since Syk deficiency in mice leads to  
blocking of B cell development, which may result in 
reduced rheumatoid factor production in patients with 
rheumatoid arthritis. Furthermore, inhibition of Syk may be 
useful for treatment or prevention of several inflammatory, 
allergic, and autoimmune diseases (e.g., cancer, asthma, 
COPD, ARDS, Crohn's disease, AIDS, psoriasis, multiple 
sclerosis, bronchitis, dermatitis, ITP, and urticaria). 
In a study in which a large number of substituted 
N-phenylpyrimidin-2-amines were tested for Syk inhibition, 
among the substituents on the core structure was also the 
1,9-diazaspiro[5.5]undecan-2-one moiety, attached to the 
core at position 9 (compounds 27a,b; Fig. 31). Compound 27b 
exhibited a better performance than compound 27a in this 
study with an IC50 < 100 nM (<1000 nM for compound 27a).80 
Figure 29. Possible CDK7 inhibitor 25 with the 1,9-diazaspiro-
[5.5]undecane as a substituent. 
MNK inhibitors. Another specific anticancer approach 
is the inhibition of MAP kinase signal-integrating kinases 
(MNKs). One of the functions of MNKs (MNK1 and 
MNK2) is the phosphorylation of eukaryotic initiation 
factor 4E (eIF4E) at serine 209.77 Eukaryotic initiation 
factor 4E is dysregulated in cancers (e.g., leukemia, breast 
and prostate cancer), and its overexpression can cause 
neoplastic transformation in cells. It is believed that 
phosphorylation of eIF4E is necessary for its oncogenic 
activity. Because this phosphorylation is done by MNKs, 
developing an antagonist for MNKs may prove useful in 
the treatment of eIF4E dependent cancers.78 
Herein the 1,9-diazaspiro[5.5]undecane moiety was used 
as a substituent attached to a polycyclic aromatic core via 
position 9 (compounds 26a–c; Fig. 30).78 Compounds 26a–c 
presented good results in this study inhibiting MNK1 and 
MNK2 with IC50 values of <0.1 μM in all cases. 
Figure 30. MNK inhibitors 26a–c. 
Spleen tyrosine kinase inhibitors. Spleen tyrosine 
kinase (Syk) is a protein tyrosine kinase, which is an 
important mediator for immunoreceptor signaling in 
Leucine-rich repeat kinase inhibitors. A number of 
compounds with a 3-(pyridin-4-yl)-1H-indazole core were 
synthesized and tested for inhibition of leucine-rich repeat 
kinase 2 (LLRK2).81 Biochemical in vitro studies have 
shown that mutant LLRK2 harboring proteins associated 
with Parkinson's disease have increased kinase activity and 
decreased GTP hydrolysis. This suggests that LLRK2 
inhibitors may block aberrant LLRK2-dependent signaling 
in Parkinson's disease and other neurodegenerative diseases 
(e.g., Lewy body dementia).82 
In this study, the IC50 values for inhibition of LLRK2 
were initially tested. A reasonable IC50 value of 14 nM was 
found for the 1,9-diazaspiro[5.5]undecan-2-one derivative 
28 (Fig. 32).81 The best IC50 values were below 0.6 nM. 
Figure 31. Compounds 27a,b tested as Syk inhibitors. 
RORγ inhibitors. A large number of multisubstituted 
arene-fused piperidines were tested for inhibition of 
retinoid-related orphan receptor gamma 2 (RORγ2).83,84 
Figure 32. LLRK2 inhibitor 28. 
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One of the compounds used in this study had a 4,5-benzene-
fused 1,9-diazaspiro[5.5]undecan-2-one moiety (compound 
29; Fig. 33). The IC50 value for compound 29 was good at 
31 nM, whereas the best performing compounds had IC50 
values of 10 nM.83 
Depending on what arene-fusion pattern was to be 
realized a different bond between two of the atoms 1–5 
could be formed in the final step of the ring closure, with 
the exception of the bond between carbons 4 and 5. 
Substitution at position 9 was sometimes included before 
ring-closure steps, but in most cases a protected piperidin-
4-one was used, allowing derivatization after cyclization. 
Substitution at position 1 was often included before the 
final ring-closing step. Besides arene fusion, the most 
important feature is the presence of a carbonyl at position 
2, often found in combination with arene fusion. 
Substitution on carbons 7, 8, 10, or 11 was rarely found, 
likely also due to the use of piperidine starting materials 
that did not contain any such substitution beforehand. 
2.1. 4,5-Arene-fused scaffolds 
Arene fusion at positions 4 and 5 of the 1,9-diazaspiro-
[5.5]undecane spirocyclic system has been the most 
common feature in search of compounds with biological 
activity against several targets. These structures often 
present a 4,5-benzene fusion and may also contain a 
carbonyl at position 2. The key transformation for the 
synthesis of this type of compounds is the one hundred 
year-old Pictet–Spengler reaction.86,87 In this reaction, a 
readily available phenethyl amine derivative (or tryptamine 
derivative) undergoes intramolecular electrophilic aromatic 
substitution after condensation with a piperidin-4-one 
derivative (or synthetic equivalent). 
For example, Sasikumar et al. utilized this reaction to 
synthesize 4,5-benzene-fused 1,9-diazaspiro[5.5]undecanes 
5a–f in search of bioactive compounds prepared for MCH-R1 
antagonism (Scheme 1).23 Phenethyl amine 31 and Boc-
protected piperidin-4-one underwent the Pictet–Spengler 
reaction to afford spiroisoquinoline 32. Compound 32 was 
then demethylated by the reaction of boron tribromide. 
Reintroduction of the Boc group (it was undesirably 
eliminated in the first step), followed by triflation of the 
phenolic hydroxyl group using PhNTf2 and subsequent 
Suzuki coupling88 with 3-cyanophenylboronic acid yielded 
the biaryl compound 33. Alkylation of compound 33 at 
position 1 using methyl 2-bromoacetate afforded acetate 
34. Then, acylation of 3,5-dichloroaniline with ester 34 in 
the presence of NaH in THF gave the corresponding amide. 
Elimination of the Boc group was achieved by 
trifluoroacetic acid to afford the free amine at position 9 of 
Figure 33. RORγ inhibitor 29 containing an arene-fused diaza-
spiro substituent. 
CC chemokine receptor type 1 inhibitors. Finally, on 
the search of CC chemokine receptor type 1 (CCR1) 
inhibitors, a library of 264 oxepine derivatives was 
synthesized. Three 4,5-benzene-fused 1,9-diazaspiro[5.5]-
undecanes were attached at position 9 via a propylene 
linker to two of the oxepine core structures (compounds 
30a–f; Fig. 34).85 
This library was developed for treating diseases asso-
ciated with aberrant leukocyte recruitment and/or activation 
or mediated by chemokines or chemokine receptor function 
(e.g., rheumatoid arthritis, atherosclerosis, arteriosclerosis, 
type 1 diabetes mellitus, Crohn's disease, psoriasis, 
multiple sclerosis). Inhibition of CCR1 was only deter-
mined for selected compounds from the library, excluding 
those with the diazaspiro substituents.85 
2. SYNTHESIS 
The choice of the method of synthesis of the desired 
1,9-diazaspiro[5.5]undecanes depends on the position of 
the arene ring fusion to the spirocyclic core. All encoun-
tered examples are summarized in Figure 35: they include 
2,3-, 3,4-, and 4,5-arene-fused 1,9-diazaspiro[5.5]undecanes, 
as well as a few examples of completely saturated core 
structures. The arene fusion location determines which 
bond is made last to perform the cyclization to the 
diazaspiro compound. In all the syntheses of these spiro 
dipiperidines, a 4-substituted piperidine derivative (most 
often a piperidin-4-one) was used as a template and the 
other piperidine ring was constructed at this position 4. 
N
Y
N ( )3
30a–f
a Y = CH2, R1 = H, R2 = H
b Y = CO, R1 = H, R2 = H
c Y = CO, R1 = Me, R2 = H
d Y = CH2, R1 = H, R2 = CN
e Y = CO, R1 = H, R2 = CN
f Y = CO, R1 = Me, R2 = CN
O
R2
R1
MeO
Figure 34. Oxepine core compounds 30a–f with 4,5-benzene-
fused 1,9-diazaspiro[5.5]undecane substituents. 
N
U
V
X
Y
N
R1R2
R1 = alkyl, aryl, carbonyl
R2 = H, alkyl, aryl, carbonyl
Y = CH2, CO
U, V, X = CH2
X, Y = arene-fused; U, V = CH2
V, X = arene-fused; U = CH2, CHCO2H
U, V = arene-fused; X = CH2
Figure 35. General structure of the synthesized 1,9-diazaspiro-
[5.5]undecanes. 
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the diazaspiro core, which was used for reductive amina-
tion of aldehydes and ketones under standard reaction 
conditions (NaBH(OAc)3 as reductant) furnished the final 
compounds 5a–f. This route allowed the synthesis of 
4,5-benzene-fused 1,9-diazaspiro[5.5]undecane core with 
three variation points: in the condensed aryl group and at 
positions 1 and 9. A library of compounds was synthesized 
using this methodology to optimize the binding affinity of 
these antagonists of MCH-R1. 
A similar strategy was also employed by Rutjes and 
coworkers to synthesize a 13-compound library of 
4,5-indole-fused 1,9-diazaspiro[5.5]undecanes and an 
isolated example of 4,5-pyrrole-fused 1,9-diazaspiro[5.5]-
undecane (Scheme 2).89 The starting piperidin-4-ones 35a–c 
were enantio- and diastereoselectively synthesized by two 
consecutive Mannich reactions.90,91 Then, the corresponding 
imines were preformed with substituted tryptamines 
(R = H, 5-F, 5-OH, and 6-OMe), 2-(2-indolyl)ethanamine, 
or 2-(2-pyrrolyl)ethanamine using Ti(Oi-Pr)4 in THF at 21°C. 
Finally, the Pictet–Spengler reactions were carried out by 
addition of trifluoroacetic acid to diastereoselectively 
afford a 13-compound library of 4,5-indole-fused 1,9-
diazaspiro[5.5]undecanes 36a–c and 38a (the indole fusion 
presents a different orientation in the latter case) and a 4,5-
pyrrole-fused 1,9-diazaspiro[5.5]undecane (37a) in yields 
from 37 to 80% after two steps. 
The Pictet–Spengler reaction can also be employed to 
synthesize 1,9-diazaspiro[5.5]undecan-2-ones by using the 
corresponding amide derivative of a phenethyl amine. If an 
amide instead of an amine was used, elevated temperatures 
(80–120°C) in combination with polyphosphoric acid were 
employed.11,30 This method was utilized by Poindexter and 
coworkers for the synthesis of NPY antagonists 3a–e 
(Scheme 3).11 Thus, phenylacetamide 39 was reacted with 
1-benzylpiperidin-4-one and polyphosphoric acid at 100°C 
for 24 h to obtain the corresponding benzylated 
4,5-benzene-fused 1,9-diazaspiro[5.5]undecane in 47% 
yield, which afforded the target scaffold 40 upon debenzy-
lation under standard conditions in 93% yield. Compound 
40 was alkylated with several alkylating agents to yield the 
final compounds 3a–e in variable yields (18–58%). 
Instead of a piperidin-4-one derivative for the Pictet–
Spengler reaction, an acetal-protected piperidin-4-one in a 
form of dioxane or dioxolane may also be used as 
reactant.14 Further substitution at position 9 of 4,5-benzene-
fused 1,9-diazaspiro[5.5]undecanes is usually introduced 
by reactions with many different reagents (e.g., alkyl 
chlorides or triflates, carboxylic acids, acyl chlorides, 
Scheme 1  
Scheme 2  
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esters, anhydrides, aldehydes, ketones, terminal alkenes, 
oxiranes, and aziridines),23,30,44 as exemplified in Schemes 
1, 3, 4, and 8. 
2.2. 3,4-Arene-fused scaffolds 
The use of 3,4-arene-fused 1,9-diazaspiro[5.5]undecanes 
has been less frequent than that of its 4,5-arene-fused 
counterparts. New synthetic pathways have been developed 
to make the 1,9-diazaspiro derivatives with this type of 
arene fusion. 
In a procedure developed by Menhaji-Klotz et al. to 
access ACC inhibitors with a 3,4-pyrazole-fused spiro-
cyclic moiety a pyrazole derivative was coupled to ethyl 
piperidine-4-carboxylate, after which a ring closing yielded the 
desired 3,4-pyrazole-fused diazaspiro core (Scheme 4).4,5 
The necessary iodomethyl pyrazole 43 was obtained in five 
steps from pyrazole 41 through compound 42, using the 
Sandmeyer reaction as the key step for the transformation 
NH2→Br.92 Deprotonation of piperidine 44 using LiHMDS 
and subsequent alkylation with iodide 43 afforded 
carboxylic acid 45, after hydrolysis of the corresponding 
ester under standard conditions (63% yield after four 
steps). Carboxylic acid 45 was then converted into an acyl 
azide by using diphenylphosphoryl azide, which underwent 
a Curtius rearrangement93 to give isocyanate 46 after 2 h at 
85°C in toluene in 91% yield. Because of safety concerns 
with the Curtius reaction on large scale, transformation of 
compound 45 into compound 46 was optimized in flow. 
The ring closing reaction to give diazaspiro compound 47 
was performed at –42°C using s-BuLi or t-BuLi in 
quantitative yield. Further derivatization to synthesize the 
final ACC inhibitors 1 was performed by Boc deprotection 
using HCl/dioxane and subsequent amide formation with 
the corresponding carboxylic acids, propylphosphonic 
anhydride (T3P), and trimethylamine at room temperature. 
A similar approach was used to make compound 2 which 
also showed good ACC inhibition.5 Another procedure 
featured a similar synthesis for more ACC inhibitors 
including different N-pyrazole substitutions, as well as 
bridging structures (e.g., 8,10-ethano bridge).4 
A different method for the preparation of 3,4-benzene-
fused 1,9-diazaspiro[5.5]undecanes was developed by 
Stoyanova et al. This method was used as a one-step 
procedure with an imine as starting material (instead of a 
derivative of piperidin-4-one; Scheme 5).94 Anhydride 48 
and ketimine 49 were stirred in 1,2-dichloroethane at room 
temperature to form diazaspiro compound 50 in excellent 
yield after filtration and washing with dichloromethane. 
Acid 50 was further transformed into five different amides, 
but no application for these compounds was pursued. 
Another short synthesis of these 3,4-benzene- and, as the 
only example in the literature, 3,4-thiophene-fused deriva-
Scheme 3  
Scheme 4 
Scheme 5  
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tives was reported by Stanetty and coworkers in which 
methyl 1-methylpiperidine-4-carboxylate (51) was used as 
starting material (Scheme 6).95 Piperidine 51 was alkylated 
with benzyl bromide and (2-thienyl)methyl chloride after 
deprotonation with lithium diisopropylamide (LDA) to 
obtain compounds 52a and 52b, respectively, in good 
yields. Hydrolysis of esters 52a,b to the corresponding 
carboxylic acids was performed by refluxing with 
concentrated hydrochloric acid. Then, a Friedel–Crafts 
reaction96 using polyphosphoric acid yielded the corres-
ponding cyclic ketones 53a,b. These ketones were trans-
formed into oximes by treatment with hydroxyl amine 
hydrochloride and pyridine in ethanol. The oximes 
underwent a Beckmann rearrangement97 upon treatment 
with polyphosphoric acid to afford the final products 54a 
and 54b in 91 and 50% yield, respectively. 
Another synthesis of 3,4-benzene-fused 1,9-diazaspiro-
[5.5]undecanes was developed by Brugger et al. and used 
the strategy of transforming the piperidin-4-one carbonyl 
carbon into spiro carbon atom (Scheme 7).50 The synthesis 
of the mGluR4 modulator 11a commenced with the 
synthesis of amide 56 by the reaction of p-anisidine and 
aroyl chloride 55 in quantitative yield. The treatment of 
amide 56 with 2 equiv of BuLi generated a dianion that 
was selectively hydroxyalkylated at the methyl group with 
1-(3,4-difluorobenzyl)piperidin-4-one to afford hydroxy 
amide 57 in poor yield (37%). Finally, this amide 
underwent cyclization via an SN1 mechanism to diazaspiro 
11a by reaction with polyphosphoric acid in a fair yield. 
2.3. 2,3-Arene-fused scaffolds 
The most rare fusion pattern among the arene-fused 
diazaspiro compounds is the arene-fusion at positions 2 and 
3. A method to synthesize such arene-fused 1,9-diazaspiro-
[5.5]undecanes was presented by Brown and coworkers 
(Scheme 8).57 
Scheme 7 
Scheme 8 
Scheme 6 
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One of the examples presented in this study was the 
synthesis of imine 58 by condensation of Boc-protected 
piperidin-4-one with 2,4-dimethylaniline. Imine 58 was 
used in the next step without further purification. Nucleo-
philic addition of isobutenyllithium (Grignard reagents 
have also been used for this reaction)98 to imine 58 yielded 
piperidine 59 in poor yield, which upon treatment with 
sulfuric acid underwent cyclization by a Friedel–Crafts 
alkylation to give the 2,3-benzene-fused 1,9-diazaspiro[5.5]-
undecane 60. Additionally, sulfuric acid removed the Boc 
group, leaving position 9 available for further derivati-
zation. For example, compound 60 was further transformed 
into compounds 14a,b on the quest for α-tocopherol 
analogs under standard reductive amination and alkylation 
conditions.57 
2.4. Aliphatic scaffolds 
The number of biologically active 1,9-diazaspiro[5.5]-
undecanes without arene fusion throughout the literature is 
significantly lower than their arene-fused counterparts. 
Although the absence of arene fusion is less common when 
the 1,9-diazaspiro[5.5]undecanes were used as core struc-
tures of the respective studies, they were encountered more 
often when they were used as substituents of other main 
structures. Gracias et al. developed a method to make a 
1,8-diazaspiro[5.5]undecane with a Petasis reaction. An 
adaptation of this method was used to synthesize 1,9-diaza-
spiro[5.5]undecanes (Scheme 9).99 
sulfonic acid and converted to spiro dipiperidines 63a,b by 
ring closing metathesis catalyzed by Grubbs catalyst (5 mol %; 
second generation) in high yields. In the absence of the 
pretreatment with acid the reaction failed to undergo ring 
closure.99 
2.5. 1→9 Acyl group shift 
The study presented in this section does not describe a 
formation of the 1,9-diazaspiro[5.5]undecane core, but 
shows a rearrangement that 2,3-benzene-fused 1,9-diaza-
spiro[5.5]undecanes can undergo. A study performed by 
Vargas et al. described an acyl shift from nitrogen 1 to 
nitrogen 9 in some 2,3-benzene-fused 1,9-diazaspiro[5.5]-
undecanes 64 (Scheme 10).102 This acyl group rearrange-
ment may reduce the protection–deprotection steps needed 
to achieve the final acyl derivatives. 
Scheme 9  
The Petasis reaction is a multicomponent reaction in 
which a carbonyl, an amine, and a boronic acid (or boro-
nate) react to form substituted amines.100 In this particular 
case, the condensation of allyl amines with piperidinone 61 
resulted in imine intermediates which were then attacked 
by the allyl group of pinacol allylboronate to form secon-
dary amines 62a,b in good to very good yields. A different 
method to synthesize the same kind of amines consisted of 
a similar reaction of a piperidone derivative with allyl-
amine followed by addition of allyl magnesium bromide to 
perform a regular Grignard addition in a one-pot 
procedure.101 Then, the resulting secondary amines 62a,b 
were protected as their ammonium salts with p-toluene-
NBn
N
R1
R2 O
Me
N
N
H
R1
Me
O
R2
64 65
HCO2NH4
Pd/C, MeOH
, 10 min
a–c R1 = H, d–h R1 = Me; a,d R2 = H, b,e R2 = Me, c,f R2 = Ph,
g R2 = CH2Cl, h R2 = 4-NO2C6H4
Scheme 10  
Compounds 65a–h were synthesized with very short 
reaction times in yields averaging >84%. A clear advantage 
of this approach is that deprotection at position 9 and 
subsequent acylation could be combined. The cited study 
presented a rationale for the 1→9 acyl shift (Scheme 11).102 
Once position 9 of compounds 64 was debenzylated by 
hydrogenolysis, the resulting free secondary amine 66 
could react with the amide at position 1 through a boat 
conformation 67. The equilibrium between the two amides 
was shifted to compound 65 because the leaving group was 
an aniline instead of an amine. Proof of the intramolecular 
nature of this reaction was provided by performing the 
reaction in the presence of piperidine or morpholine, with 
no observation of acylated products of these external 
amines. 
Scheme 11 
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The present review has provided a comprehensive 
overview of the biological activity and synthesis of the 
1,9-diazaspiro[5.5]undecanes. The different forms of the 
1,9-diazaspiro[5.5]undecane core (1,2-, 2,3-, 3,4-, and 
4,5-(hetero)arene-fused and the saturated core structures) 
have been investigated in a broad range of medicinal 
applications. As a result, an impressive number of research 
publications and patents have been published in this field. 
The vast array of biological properties displayed by this 
family of compounds opens a door for the development of 
new therapeutics for a variety of diseases. The synthetic 
strategies toward these scaffolds are determined by their 
substitution pattern. It is worth mentioning that most of the 
synthetic methods start with a 4-substituted piperidine 
moiety and construct the second piperidine ring from this 
substitution at position 4. Variable cyclization methods are 
used for the generation of this spiro linkage, the Pictet–
Spengler reaction being the method of choice for the 
4,5-arene-fused scaffolds, the most common among these 
compounds. 
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